Kornimate/medical-research-clean huggingface dataset:
measurement of anti-androgen response using fluorine-18 fluorocholine pet/ct in androgen-insensitive prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to determine whether positron emission tomography / computed tomography (pet/ct) using fluorine-18 fluorocholine as an imaging agent can characterize regional responses to anti-androgen therapies in a manner that in the future aid in the customized planning of treatments for patients with androgen-insensitive prostate cancer.


Eligibility criteria:
inclusion criteria: 1. provision of written informed consent. 2. men, over 18 years of age, with histologically-confirmed diagnosis of prostate cancer 3. history of treatment by complete androgen blockade for greater than 3 months prior to enrollment 4. serum testosterone level \< 50 ng/ml. castrate testosterone levels must be from orchiectomy or current therapy with leutinizing hormone-releasing hormone agonist. 5. progressive disease evidenced by two consecutive rises in prostate specific antigen (psa) above a nadir value, with the absolute value of the latest psa \> 2. 0 ng/ml. 6. patient will be undergoing a therapeutic intervention under the supervision of his treating physician (urologist, oncologist). exclusion criteria: 1. other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or superficial transitional cell carcinoma of the bladder. 2. serious underlying medical conditions that would otherwise impair the patient's ability to undergo imaging. 3. patient weighs over 350 lbs (due to scanner weight limit). 4. clinical life expectancy \< 12 weeks. 5. participated in other radioactive drug studies where estimated total cumulative dose within 1 year is \> 0.05 sievert for whole body, active blood-forming organs, eye lens, gonads, or 0.15 sievert for other organs. 6. concurrent therapy. allowed: prior hormonal therapy; concurrent leuteinizing hormone releasing hormone (lhrh) agonist; prior surgery; prior or concurrent bisphosphonate. not allowed: concurrent anti-androgen or secondary hormonal therapy, prior or concurrent chemotherapy, concurrent radiotherapy or radioisotope therapy (e.g., strontium). other: prior radiotherapy or radioisotope therapy must be \> 12 weeks since last treatment.

Keywords: androgen insensitive prostate cancer
manual lymphatic drainage in the superior member in women in post-surgery for breast cancer

Conditions: Lymphedema

Summary: evaluate the effect of manual lymphatic drainage (mld) massage in arterial and venous circulation of the upper limb ipsilateral of women submitted after axillary lymphadenectomy breast cancer.

the aim of the study is to evaluate the effect of manual lymphatic drainage (mld) massage in arterial and venous circulation of the upper limb ipsilateral of women submitted after axillary lymphadenectomy breast cancer. will be evaluated 30 volunteers aged between 40 and 60 years, divided into 2 equal groups, submitted at mld: group 1 - volunteers who underwent surgery for breast cancer that have lymphedema, subject to manual lymphatic drainage without upper limb elevation; group 2 - volunteers who underwent surgery for breast cancer that have lymphedema, subject to manual lymphatic drainage with the upper limb elevation to 30º. data will be collected by ultrasound doppler in vein and brachial artery before, after mld, immediately after, and 30 minutes after therapeutic treatment, with and without elevation of 30°, cross over delimitation, being made a therapy session for therapeutic use with and without elevation, with interval period (washout) for seven days. the order of treatment protocols will be randomized by simple raffle for each volunteer. the data within and between groups will be evaluated by a statistical test t student or anova. otherwise it will be used kruskal-wallis followed test by dunn. data processing will be performed by software and fixed the critical level of 5% (p\<0,05).

Eligibility criteria:
inclusion criteria: * women with axillary lymphadenectomy surgery * lymphedema * aged 40-60 years. exclusion criteria: * women with muscle-tendon injury and / or joint injuries member * skin disorders * circulatory diseases.
parathyroid hormone for the treatment of humerus fractures

Conditions: Shoulder Fractures

Summary: hypothesis: the investigators want to study whether parathyroid hormone improves healing of humerus after a fracture. the investigators will assess healing of the humerus with constant score.


Eligibility criteria:
inclusion criteria: * proximal humeral fracture eligible for conservative treatment. * able to understand the protocol * signs an informed consent exclusion criteria: * liver disease * kidney disease * severe osteoporosis * malignant disease * bone metabolic disease * oral treatment with bisphosphonates during the last 3 months. * treatment with denosumab during the last 6 months. * intravenous treatment with bisphosphonates during the last 12 months.

Keywords: proximal humeral fracture
a study of ray1225 in participants with type 2 diabetes

Conditions: T2DM (Type 2 Diabetes Mellitus)

Summary: the main purpose of this study is to learn more about the tolerability of ray1225 in participants with type 2 diabetes mellitus. the study will also explore the efficacy of ray1225. the study will last about six months for each participant.


Eligibility criteria:
inclusion criteria: 1. type 2 diabetes had been diagnosed for at least 12 weeks prior to screening and one of the following conditions: 1. have t2dm controlled with diet and exercise alone; 2. are stable in dose and type on a single or in a combination of oral antidiabetic medication, metformin, α-glucosidase inhibitors or sglt-2 inhibitors only ,within 12 weeks before screening; 2. bmi ≥ 20 kg/m²； 3. fasting blood-glucose（fpg）\<15 mmol/l; 4. weight change \< 5% in the 12 weeks before screening; 5. participants (including partners) must use reliable methods of contraception during the study and until 6 months following the last dose of investigational product. exclusion criteria: 1. have type 1 diabetes mellitus； 2. severe diabetic complications, including proliferative retinopathy or maculopathy, severe diabetic neuropathy (e.g., urinary retention, urinary incontinence, and painful peripheral neuropathy), resting tachycardia, orthostatic hypotension, intermittent claudication, or diabetic foot; 3. two or more episodes of ketoacidosis, lactic acidosis, or hyperosmolar state leading to hospitalization within 24 weeks before screening; 4. had grade 3 hypoglycemic events within 12 months before screening, 5. three or more grade 2 hypoglycemic events occurred within 3 months before screening; 6. have symptoms related to hypoglycemia at screening; 7. within 6 weeks before screening, serious trauma, serious infection, or surgery that may have affected glycemic control was reported; 8. have a family or personal history of medullary thyroid carcinoma (mtc) or multiple endocrine neoplasia (men) syndrome type 2 or with thyroid nodules of unknown etiology found at screening and considered clinically significant by the investigator. 9. have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty if performed \>1 year prior to screening)
analysis of risk factors for death after blunt traumatic rupture of the thoracic aorta

Conditions: Aortic Rupture

Summary: aortic injuries after blunt thoracic trauma are compared to the great incidence of accidents relatively rare, but potentially serious leading to death at scene in most of the cases. the study was undertaken to delineate mortality and its risk factors on three different levels (pre-hospital, in-hospital and overall). between 1990 and 2003, all consecutive patients and victims with traumatic aortic rupture were retrospectively analyzed by reviewing hospital and autopsy records.

during the study period of 14 years (january 1990 to december 2003), all consecutive cases with traumatic rupture of the thoracic aorta being reported in the greater area of zurich with about one million inhabitants were included in the present study. related to the final outcome, patient data were drawn either from medical reports from the university hospital of zurich, which is a tertiary care teaching hospital and level i trauma center for the eastern part of switzerland, or from autopsy reports from the institute of forensic medicine of the university of zurich, respectively. the latter group includes all patients, who died on the scene, in a assigning primary care hospital or on the way to the university hospital of zurich. in switzerland, the criteria used for performing a full autopsy after a blunt traumatic death include all cases in which the events leading to the death are unclear or in which the cause of death is the result of suicide or extrinsic harm. both, deaths at the scene and in-hospital deaths were included in the study.

Eligibility criteria:
inclusion criteria: * during the study period of 14 years (january 1990 to december 2003), all consecutive cases with traumatic rupture of the thoracic aorta being reported in the greater area of zurich with about one million inhabitants were included in the present study exclusion criteria: * non-traumatic aortic rupture * non-traumatic aortic dissection
efficacy comparison study of steroids to control post-operative inflammation

Conditions: Inflammation; Intraocular Pressure

Summary: phacoemulsification is a quick method with less complication for cataract surgery. due to the use of ultrasonic energy, it produced more post-operative inflammation than other methods. many routes of steroid had been used to control post-operative inflammation. the investigators here compare the efficacy of single depot steroid subtenon injection (20-mg triamcinolone) with four-time-a-day steroid eye drop (0.1% dexamethasone) in controlling inflammation after uneventful phacoemulsification.

cataract is one of the most common causes of blindness in the world. surgical removal of lens is the only treatment for cataract, which now shifts from extracapsular cataract extraction to phacoemulsification. although phacoemulsification provides faster operating time and gives better optical result and rapid recovery to the patient, it causes more inflammation post-operatively compare with extracapsular cataract extraction. corticosteroids eye drops are mainly use to control intraocular inflammation after the surgery. other routes of corticosteroids have been introduced to increase the intraocular level and to increase the patient's compliance. subtenon triamcinolone injection is easy and safe. antiinflammatory effect of single subtenon triamcinolone injection lasts about 4-6 weeks. this method has been used in combination with corticosteroid eye drop to control the inflammation after cataract surgery in uveitic patients. it shows potency in controlling of intraocular inflammation with lower rate of increasing the intraocular pressure. the investigators here quantitatively compare the efficacy of subtenon 20-mg triamcinolone injection with 0.1% dexamethasone eye drop in controlling intraocular inflammation after uneventful phacoemulsification.

Eligibility criteria:
inclusion criteria: * age older than 18 years old * uncomplicated cataract patient scheduled for phacoemulsification and posterior chamber intraocular lens implantation * no history of prior intraocular procedures or any eye diseases such as uveitis, glaucoma, diabetic retinopathy * no history of systemic autoimmune diseases * no history of allergy to corticosteroids or to any component of the study medications * no history of using corticosteroids, non-steroidal anti-inflammatory drugs (nsaids), or immunomodulating agents within 3 months prior to surgery exclusion criteria: * complications occurred during cataract surgery such as ruptured posterior capsule, vitreous loss, or dropped nucleus * pregnant and lactating women

Keywords: post-operative inflammation steroid intraocular pressure
personalized exercise treatments for older veterans with motoric cognitive risk syndrome

Conditions: Motoric Cognitive Risk Syndrome

Summary: this study will begin to evaluate personalized preventative dementia treatments for veterans at risk for developing dementia. the investigators will target veterans with motoric cognitive risk syndrome (mcr), which is characterized by slow gait speed and cognitive concerns (e.g., problems with memory or concentrations).

this study will involve therapeutic exercise treatments for veterans with pre-clinical dementia syndrome. participants will either participate in functional power training, music-based walking training, or a combination of both. the study will use a sequential multiple assignment, randomized trial (smart) design. successful completion of this study will lay the foundation for subsequent research trials, contributing to valuable evidence for personalized rehabilitation medicine for older veterans.

Eligibility criteria:
inclusion criteria: 1. age 65 2. receiving va primary care 3. community-dwelling 4. motoric cognitive risky syndrome i. slow gait speed ii. subjective cognitive concerns/complaints exclusion criteria: 1. non-english speaking 2. presence of a terminal disease 3. major medical problem 4. myocardial infarction or major surgery in the previous 3 months 5. use of a walker 6. dementia diagnostic 7. mobility disability

Keywords: veterans mobility cognition sequential multiple assignment randomized trial
a study to evaluate axatilimab and corticosteroids as initial treatment for chronic graft-versus-host disease

Conditions: Chronic Graft-versus-host-disease

Summary: this study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or severe chronic graft-versus-host disease (cgvhd).


Eligibility criteria:
inclusion criteria: * ≥ 12 years of age at the time of informed consent. * new-onset moderate or severe cgvhd, as defined by the 2014 nih consensus development project criteria for clinical trials in cgvhd, requiring systemic therapy. * history of allo-hct from any donor hla type (related or unrelated donor with any degree of hla matching) using any graft source (bone marrow, peripheral blood stem cells, or cord blood). recipients of myeloablative, nonmyeloablative, or reduced-intensity conditioning are eligible. * adequate hematologic function with anc ≥ 0.5 × 109/l independent of growth factors for at least 7 days prior to study entry. * willingness to avoid pregnancy or fathering children. exclusion criteria: * received more than 1 prior allo-hct. prior autologous hct is allowed. * has overlap cgvhd, defined as simultaneous presence of features or characteristics of agvhd in a patient with cgvhd. * received more than 7 days of systemic corticosteroid treatment for cgvhd or unable to begin a prednisone dose ≥ 1.0 mg/kg per day (or methylprednisolone equivalent) for cgvhd. * received previous systemic treatment for cgvhd, including extracorporeal photopheresis. * systemic treatment with cnis or mtor inhibitors started within 2 weeks prior to c1d1. * prior treatment with csf-1r targeted therapies. * active, uncontrolled bacterial, fungal, parasitic, or viral infection. * evidence of relapse of the primary hematologic disease or treatment for relapse after the allo-hct was performed, including dlis for the treatment of molecular relapse. * history of acute or chronic pancreatitis. * active symptomatic myositis. * history or current diagnosis of cardiac disease indicating significant risk of safety for participation in the study, such as uncontrolled or significant cardiac disease. * severe renal impairment, that is, estimated crcl \< 30 ml/min measured or calculated by cockcroft-gault equation in adults and schwartz formula in pediatric participants, or endstage renal disease on dialysis. * impaired liver function, defined as total bilirubin \> 1.5 × uln and/or alt and ast \> 3 × uln in participants with no evidence of liver cgvhd. * pregnant or breastfeeding. other protocol-defined inclusion/exclusion criteria may apply.

Keywords: cgvhd
endometrial cancer lymphadenectomy trial

Conditions: Cancer of Endometrium Stage I; Cancer of Endometrium Stage II

Summary: the primary aim of this trial is to ascertain whether or not systematic pelvic and para-aortic lymphadenectomy (lne) does have a significant impact on overall survival (os) in patients with endometrial cancer (ec) figo stages i or ii and high risk of recurrence. secondary aims will be to evaluate the effect of lne on disease free survival (dfs) and quality of life, as well as the complications and side effects of lne and the number of resected lymphnodes. 640 patients with histologically confirmed ec with high risk of recurrence (stage pt1b - pt2, all histological subtypes; pt1a, g3 endometrioid or serous or clear cell ec or carcinosarcomas) will be randomized. in arm a, a total hysterectomy and bilateral salpingo-oophorectomy and in case of serous or clear cell ec additionally an omentectomy will be performed. in arm b in addition a systematic pelvic and para-aortic lne up to the level of the left renal vein will be performed.


Eligibility criteria:
inclusion criteria: 1. histologically confirmed ec of clinical stages t1b and t2 (all histological types) and stage t1a g3 type 1 (endometrioid, endometriod with squamous differentiation, mucinous) or type 2 tumors (any percentage of serous or clear cell component) or carcinosarcoma 2. a) no previous surgery concerning ec (primary surgery) or b) surgery after hysterectomy (e.g. for presumed low risk endometrial cancer) is allowed within 8 weeks after hysterectomy if no lne was performed (secondary surgery) 3. absence of bulky lymph nodes 4. performance status ecog 0-1 5. age 18 - 75 years 6. written informed consent 7. adequate compliance exclusion criteria: 1. stage pt1a, g1 or g2 tumors of type 1 histology 2. sarcomas (except for carcinosarcoma = malignant mixed müllerian tumor) 3. ec of figo stages iii or iv (except for microscopical lymph node metastases) 4. evidence of extrauterine disease by visual inspection 5. recurrent ec 6. preceding chemo-, radio, or endocrine therapy for ec 7. any concomitant disease not allowing surgery including lymphadenectomy and/or chemotherapy 8. any medical history indicating excessive peri-operative risk 9. any current medication containing considerable surgical risk (e.g. bleeding: due to oral anticoagulating agents) 10. any known disorder or circumstances making participation in trial and follow-up questionable. insufficient compliance is expected. 11. patients with second malignancies if disease or treatment might have an impact on the patient's prognosis 12. known hiv-infection or aids 13. simultaneous participation in other clinical trials if not permitted by the steering committee (translational or qol studies not interfering with the objectives of eclat are allowed)
gait rehabilitation in diplegic children

Conditions: Cerebral Palsy; Spastic Diplegia

Summary: background: standing and walking serve an individual's basic need to move from place to place, and both are the most common activities that people do on a daily basis. aim: to investigate the combined effect of botulinum toxin a (bont-a) injection and ankle weight on the gait of diplegic children who are using ankle foot orthoses.

methods: sixty children with spastic diplegia were included in this prospective, controlled trial. children were divided into three groups, each with 20 patients: group 1 received classical gait rehabilitation; group 2 received the same gait training while adding ankle weight ; and group 3 received the same as group 2 plus botulinum toxin injection. the modified ashworth scale (mas),knee range-of-motion measures, and hoffman /myogenic reflex ratio were used to examine patients before the commencement of treatment and post-treatment.

Eligibility criteria:
inclusion criteria: * diagnosed as spastic diplegia. * they were able to follow simple verbal instructions. * the use of ankle foot orthoses. * spasticity grade of 1+ or 2 in both calf and hamstring muscles according to modified ashworth's scale (mas). * level i or ii on the gross motor function classification system (gmfcs). exclusion criteria: * fixed contractures or deformities in the lower limbs. * surgical orthopedic intervention. * botulinum a injection or use of neuromuscular blockers in the previous 6 months before the start of study.

Keywords: gait diplegia ankle weight botox injection
maximizing acute kidney injury end-point intervention post-discharge (make-it) study

Conditions: Acute Kidney Injury

Summary: this purpose of this pilot and feasibility study is to determine whether attending an acute kidney injury (aki) clinic after discharge from the hospital impacts prescription medicine use, blood pressure and recovery of kidney function as compared to usual care.

participants with moderate to severe acute kidney injury (aki) who are discharged from participating centers (the university of alabama at birmingham hospital, vanderbilt university medical center, university of kentucky) will be randomized to coming to a dedicated aki clinic at one of the three recruitment centers for up to four visits over 3 months or usual care. at the visits to the aki follow-up clinics, medicine reconciliation will be done, blood pressure will be measured, information on hospitalizations and other adverse events will be taken and blood and urine samples will be collected to check kidney function and store samples to measure biomarkers of aki. participants randomized to usual care will be contacted by telephone to review medications currently being taken and to collect information on hospitalizations and other adverse events. the primary outcome measures will be include both process of care and clinical outcomes.

Eligibility criteria:
inclusion criteria: * patients age 18 years and older * patients who have developed moderate to severe aki in the hospital, defined as: 1. at least a doubling of peak creatinine from baseline or receipt of dialysis while in the hospital 2. aki of any degree in individuals with an estimated glomerular filtration (egfr) rate \< 60 ml/min/1.73m2 at baseline 3. aki of any degree whose discharge creatinine does not return to within 50% of baseline. * able to provide signed informed consent exclusion criteria: * patients with a history of kidney transplant * patients who, in the opinion of the investigator, are not suitable to participate in the study * unable to obtain written informed consent * prisoners or pregnant patients